Close
To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked IRAS Number, which will take you to the UCLH Find a Study database.
Additional early phase clinical trials recruiting Sarcoma cohorts may be found in the Advanced Solid Tumour Trials Portfolio page.
FaR-RMSAn overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma | |
|---|---|
| IRAS Number: | 254931 |
| Principal Investigator: | Dr. Maria Michelagnoli |
| Drug Class/ Treatment: | Trial of various Immunotherapy, Targeted Therapy Agents and Radiotherapy. |
| Patient Population: | Newly Diagnosed and Relapsed Rhabdomyosarcoma (RMS) Age >12 months and ≤25 years |
| Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) | |
SPEARHEAD-1A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma | |
|---|---|
| IRAS Number: | 265659 |
| Principal Investigator: | Prof. Sandra Strauss |
| Drug Class/ Treatment: | ADP-A2M4 SPEAR™ T Cells - Genetically Modified T-Cells targeting MAGEA4 (Melanoma-Associated Antigen 4) |
| Patient Population: | Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Age 16 - 75 |
| Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) | |
LIGHTBEAM-U01 (MK-9999-01a Sub Study)LIGHTBEAM-U01 Sub study 01A: A Phase 1/2 Sub-study to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Paediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumours
| |
|---|---|
| IRAS Number: | 1008911 |
| Pincipal Investigator: | Dr Rachel Windsor |
| Drug Class/ Treatment: | Zilovertamab Vedotin - Antibody-Drug Conjugate |
| Patient Population: | Paediatric Patients (1 - <18 Years):
Paediatric and Young Adult Patients (Birth - 25 Years):
|
| Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) | |
